{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:00:11Z","timestamp":1793685611213,"version":"4.5.1"},"reference-count":81,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Systemic advanced therapies, including biologic drugs and Janus kinase (JAK) inhibitors, have revolutionized atopic dermatitis management. The increasing number of available options for such complex diseases demands careful treatment selection for each patient, considering numerous variables. Comparative analyses of these treatment modalities in the real world are still limited. Only a faithful basal characterization would enable posterior meaningful and accurate comparisons of the efficacy and safety profiles of these groups of drugs. This communication focuses on describing and comparing the baseline demographics and comorbidities of patients with atopic dermatitis currently treated with biologic therapies versus JAK inhibitors in our setting. Methods: We conducted an observational, descriptive, and ambispective study across three hospitals covering a population of over 500,000 inhabitants from January 2019 to December 2024. Baseline demographic data, anthropometric measures, lifestyle factors, cardiovascular risk factors, and comorbidities were analyzed using descriptive and inferential statistics. Additionally, basal severity and effectivity over time have also been compared. Results: A total of 150 patients were analyzed. A total of 102 had received biological therapies (dupilumab or tralokinumab), whereas 48 patients had received JAK inhibitors (upadacitinib, baricitinib, or abrocitinib). Ages ranged from 11 to 76 years. The overall cohort had a mean age of 35.87 \u00b1 14.37 years and a male predominance (male-to-female ratio 1.63:1). Hypertension was more prevalent in the JAK inhibitors group (p = 0.0175), yet other cardiovascular risk factors, body measurements, atopic and non-atopic comorbidities, and disease severity were comparable across both groups. Conclusions: This study helped to characterize the baseline characteristics of patients treated with advanced systemic therapies in a real-world clinical setting. It pointed to just slight differences between the profiles of patients treated with biologics versus JAK inhibitors. This homogeneity in baseline characteristics sets the ground for further future comparisons of treatment outcomes in this cohort as potential confounding factors related to group imbalances are minimized.<\/jats:p>","DOI":"10.3390\/jcm14041291","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T03:41:47Z","timestamp":1739763707000},"page":"1291","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Real-World Analysis of Baseline Demographic Characteristics and Comorbidities in Atopic Dermatitis Patients Initiating Biologics Versus JAK Inhibitors"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-3727","authenticated-orcid":false,"given":"Alvaro","family":"Prados-Carmona","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Cecilio, 18016 Granada, Spain"},{"name":"Instituto Biosanitario de Granada, Ibs, 18001 Granada, Spain"},{"name":"Escuela Internacional de Posgrado, Universidad de Granada, 18001 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-3671","authenticated-orcid":false,"given":"Francisco J.","family":"Navarro-Trivi\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Cecilio, 18016 Granada, Spain"},{"name":"Instituto Biosanitario de Granada, Ibs, 18001 Granada, Spain"},{"name":"Department of Contact Eczema and Immunoallergic Diseases, Dermatology, Hospital Universitario San Cecilio, 18007 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husein","family":"Husein-ElAhmed","sequence":"additional","affiliation":[{"name":"Instituto Biosanitario de Granada, Ibs, 18001 Granada, Spain"},{"name":"Department of Dermatology, Hospital Universitario de Baza, 18800 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Cecilio, 18016 Granada, Spain"},{"name":"Instituto Biosanitario de Granada, Ibs, 18001 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","article-title":"Atopic Dermatitis","volume":"22","author":"Bieber","year":"2010","journal-title":"Ann. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/jcm4050858","article-title":"Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics","volume":"4","author":"Mansouri","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"ISAAC Phase Three Study Group Global Variations in Prevalence of Eczema Symptoms in Children from ISAAC Phase Three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/imr.12545","article-title":"The Interplay between Genetic and Environmental Factors in the Pathogenesis of Atopic Dermatitis","volume":"278","author":"Otsuka","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","article-title":"A Systematic Review and Meta-Analysis of the Regional and Age-Related Differences in Atopic Dermatitis Clinical Characteristics","volume":"80","author":"Yew","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial Differences in Atopic Dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1038\/jid.2014.126","article-title":"Exome Sequencing of Filaggrin and Related Genes in African-American Children with Atopic Dermatitis","volume":"134","author":"Margolis","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the Complexities of Atopic Dermatitis: Shifting Paradigms in Treatment Approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.det.2017.02.006","article-title":"An Update on the Pathophysiology of Atopic Dermatitis","volume":"35","author":"Malik","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/jid.2009.71","article-title":"The Role of Leukocytes, Keratinocytes, and Allergen-Specific IgE in the Development of Atopic Dermatitis","volume":"129","author":"Werfel","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.anai.2017.09.055","article-title":"Immunologic, Microbial, and Epithelial Interactions in Atopic Dermatitis","volume":"120","author":"Brunner","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jvc2.537","article-title":"Role of Interleukins in Dermatology: Exploring the Immune Mechanisms in Skin Diseases","volume":"3","author":"Corell","year":"2024","journal-title":"JEADV Clin. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/pde.15410","article-title":"Mental Health Comorbidity in Youth with Atopic Dermatitis: A Narrative Review of Possible Mechanisms","volume":"40","author":"Radtke","year":"2023","journal-title":"Pediatr. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/all.15917","article-title":"Cascade of Atopic Dermatitis Comorbidities in Children after Birth for 15 Years","volume":"79","author":"Kim","year":"2024","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2021.11.014","article-title":"Real-World Comorbidities of Atopic Dermatitis in the US Adult Ambulatory Population","volume":"86","author":"Roh","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/jdv.19686","article-title":"Epidemiology of Mental Health Comorbidity in Patients with Atopic Dermatitis: An Analysis of Global Trends from 1998 to 2022","volume":"38","author":"Cai","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/09546634.2019.1702147","article-title":"Concomitant Atopic Dermatitis and Psoriasis\u2014A Retrospective Review","volume":"32","author":"Barry","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic Dermatitis and Psoriasis: Two Different Immune Diseases or One Spectrum?","volume":"48","author":"Krueger","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.amjmed.2015.05.041","article-title":"Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis","volume":"128","author":"Hjuler","year":"2015","journal-title":"Am. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaci.2014.11.023","article-title":"Eczema and Cardiovascular Risk Factors in 2 US Adult Population Studies","volume":"135","author":"Silverberg","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Olbrich, H., Kridin, K., Hern\u00e1ndez, G., Zirpel, H., Sadik, C.D., Terheyden, P., Tha\u00e7i, D., Ludwig, R.J., and Boch, K. (2024). Increased Cardiovascular Risks and Mortality in Prurigo Nodularis: A Global Cohort Study. EBioMedicine, 103.","DOI":"10.1016\/j.ebiom.2024.105123"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/all.12685","article-title":"Association between Adult Atopic Dermatitis, Cardiovascular Disease, and Increased Heart Attacks in Three Population-Based Studies","volume":"70","author":"Silverberg","year":"2015","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaci.2022.12.824","article-title":"In Search of the Holy Grail in Atopic Dermatitis: Will Dupilumab Become the First Disease-Modifying Atopic Dermatitis Drug?","volume":"151","author":"Bieber","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMra1011040","article-title":"Filaggrin Mutations Associated with Skin and Allergic Diseases","volume":"365","author":"Irvine","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/exd.13336","article-title":"Systemic Immune Mechanisms in Atopic Dermatitis and Psoriasis with Implications for Treatment","volume":"27","author":"Krueger","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cyto.2014.11.023","article-title":"New Pathogenic and Therapeutic Paradigms in Atopic Dermatitis","volume":"73","author":"Malajian","year":"2015","journal-title":"Cytokine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The Translational Revolution in Atopic Dermatitis: The Paradigm Shift from Pathogenesis to Treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s13555-023-00920-4","article-title":"Emerging Systemic Treatments for Atopic Dermatitis","volume":"13","author":"Ferrucci","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Makowska, K., Nowaczyk, J., Blicharz, L., Wa\u015bkiel-Burnat, A., Czuwara, J., Olszewska, M., and Rudnicka, L. (2023). Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010781"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/14712598.2019.1583204","article-title":"Towards Personalized Treatment in Atopic Dermatitis","volume":"19","author":"Thijs","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bjd.12975","article-title":"Immunological and Molecular Targets of Atopic Dermatitis Treatment","volume":"170","author":"Wollenberg","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/ACI.0000000000000306","article-title":"The \u201comics\u201d Revolution: Redefining the Understanding and Treatment of Allergic Skin Diseases","volume":"16","author":"Oliva","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e15909","DOI":"10.1111\/dth.15909","article-title":"Real-world Evidence of Biological Agents in Dermatology: A Review of Its Applications, Advantages, and Limitations","volume":"35","author":"Shen","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis","volume":"65","author":"Menter","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/bjd.17849","article-title":"A Standardization Approach to Compare Treatment Safety and Effectiveness Outcomes between Clinical Trials and Real-world Populations in Psoriasis","volume":"181","author":"Yiu","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ruiz-Villaverde, R., Rodriguez-Fernandez-Freire, L., Cebolla-Verdugo, M., Prados-Carmona, A., Hern\u00e1ndez-Montoya, C., Armario-Hita, J.C., and Gal\u00e1n-Guti\u00e9rrez, M. (2024). Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain. Life, 14.","DOI":"10.3390\/life14030281"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/14712598.2013.758708","article-title":"New Era of Biologic Therapeutics in Atopic Dermatitis","volume":"13","author":"Dhingra","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic Dermatitis Yardstick: Practical Recommendations for an Evolving Therapeutic Landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clindermatol.2017.03.012","article-title":"Systemic Therapies in Atopic Dermatitis: The Pipeline","volume":"35","year":"2017","journal-title":"Clin. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic Dermatitis: An Expanding Therapeutic Pipeline for a Complex Disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_41","first-page":"349","article-title":"Atopic Dermatitis\u2014Perspectives and Unmet Medical Needs","volume":"21","author":"Buhl","year":"2023","journal-title":"JDDG J. Ger. Soc. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Marfil-Cant\u00f3n, M., Prados-Carmona, A., Cebolla-Verdugo, M., Husein-ElAhmed, H., Campos, F., and Ruiz-Villaverde, R. (2024). Anti-OX40 Biological Therapies in the Treatment of Atopic Dermatitis: A Comprehensive Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226925"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2013.02.044","article-title":"Efficacy of Allergen-Specific Immunotherapy for Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"132","author":"Bae","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2133.2011.10775.x","article-title":"Efficacy and Safety of Topical WBI-1001 in Patients with Mild to Severe Atopic Dermatitis: Results from a 12-Week, Multicentre, Randomized, Placebo-Controlled Double-Blind Trial","volume":"166","author":"Bissonnette","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Schneeweiss, M.C., Glynn, R.J., Wyss, R., Anand, P., Jin, Y., Landon, J., Mostaghimi, A., Merola, J.F., Silverberg, J.I., and Rosmarin, D.M. (J. Investig. Dermatol., 2024). A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice, J. Investig. Dermatol., Epub ahead of print.","DOI":"10.1016\/j.jid.2024.08.034"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic Treatments for Atopic Dermatitis (Eczema): Systematic Review and Network Meta-Analysis of Randomized Trials","volume":"152","author":"Chu","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative Efficacy and Safety of Systemic Therapies Used in Moderate-to-severe Atopic Dermatitis: A Systematic Literature Review and Network Meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.19897","article-title":"Dupilumab Treatment in Patients with Atopic Dermatitis: A Comparative Cohort Study between the Netherlands and Japan Shows a Discrepancy in Patient-reported Outcome Measures","volume":"185","author":"Fujimoto","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"113383","DOI":"10.1016\/j.intimp.2024.113383","article-title":"Comparative Effectiveness of Upadacitinib versus Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study","volume":"143","author":"Yang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(03)02539-8","article-title":"Consensus Conference on Pediatric Atopic Dermatitis","volume":"49","author":"Eichenfield","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of Care for the Management of Atopic Dermatitis: Section 1. Diagnosis and Assessment of Atopic Dermatitis Work Group","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40257-017-0299-4","article-title":"Systematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials","volume":"19","author":"Vakharia","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic Features of Atopic Dermatitis","volume":"60","author":"Hanifin","year":"1980","journal-title":"Acta Derm. Venereol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1468-3083.2006.01664.x","article-title":"Comparative Efficacy of Hanifin and Rajka\u2019s Criteria and the UK Working Party\u2019s Diagnostic Criteria in Diagnosis of Atopic Dermatitis in a Hospital Setting in North India","volume":"20","author":"De","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/bjd\/ljad339","article-title":"Global Epidemiology of Atopic Dermatitis: A Comprehensive Systematic Analysis and Modelling Study","volume":"190","author":"Tian","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/jdv.17929","article-title":"Prevalence and Characteristics of Atopic Dermatitis among Young Adult Females and Males\u2014Report from the Swedish Population-based Study BAMSE","volume":"36","author":"Johansson","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of Atopic Dermatitis in Adults: Results from an International Survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/pde.15263","article-title":"Differences in Prescriptions for Systemic Medications and Nonsteroidal Topicals among Children with Atopic Dermatitis","volume":"40","author":"Ahmed","year":"2023","journal-title":"Pediatr. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2019.05.102","article-title":"Placebo Responses in Randomized Controlled Trials for Systemic Therapy in Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of Care for the Management of Atopic Dermatitis in Adults with Phototherapy and Systemic Therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40257-023-00837-w","article-title":"Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors","volume":"25","author":"Kim","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Calabrese, L., D\u2019Onghia, M., Lazzeri, L., Rubegni, G., and Cinotti, E. (2024). Blocking the IL-4\/IL-13 Axis versus the JAK\/STAT Pathway in Atopic Dermatitis: How Can We Choose?. J. Pers. Med., 14.","DOI":"10.3390\/jpm14070775"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zhang, J., Li, W., Gong, M., Gu, Y., Zhang, H., Dong, B., Guo, Q., Pang, X., Xiang, Q., and He, X. (2023). Risk of Venous Thromboembolism with Janus Kinase Inhibitors in Inflammatory Immune Diseases: A Systematic Review and Meta-Analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1189389"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","article-title":"Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8804","DOI":"10.1038\/ncomms9804","article-title":"Meta-Analysis Identifies Seven Susceptibility Loci Involved in the Atopic March","volume":"6","author":"Marenholz","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02980.x","article-title":"The Role of Microorganisms in Atopic Dermatitis","volume":"144","author":"Baker","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2011.01.053","article-title":"Contrasting Pathogenesis of Atopic Dermatitis and Psoriasis\u2014Part I: Clinical and Pathologic Concepts","volume":"127","author":"Nograles","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e15636","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis","volume":"35","author":"Wan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/7527859","article-title":"Atopic Dermatitis and Psoriasis as Overlapping Syndromes","volume":"2020","author":"Bozek","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wa\u015bkiel-Burnat, A., Osi\u0144ska, M., Sali\u0144ska, A., Blicharz, L., Goldust, M., Olszewska, M., and Rudnicka, L. (2021). The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications. Cells, 10.","DOI":"10.3390\/cells10123397"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1203475418824079","article-title":"The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature","volume":"23","author":"Crowley","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/exd.14129","article-title":"Understanding the Significance of Cytokines and Chemokines in the Pathogenesis of Alopecia Areata","volume":"29","author":"Ito","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic Dermatitis (Eczema) Guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE\u2013 and Institute of Medicine\u2013Based Recommendations","volume":"132","author":"Chu","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ijd.17501","article-title":"Infection Risk with JAK Inhibitors in Dermatoses: A Meta-analysis","volume":"64","author":"Ireland","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","article-title":"The Safety of Systemic Janus Kinase Inhibitors in Atopic Dermatitis: A Systematic Review and Network Meta-Analysis","volume":"78","author":"Alves","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.19426","article-title":"The Safety of Systemic Janus Kinase Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"38","author":"Yoon","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","article-title":"Comparative Safety of Oral Janus Kinase Inhibitors versus Dupilumab in Patients with Atopic Dermatitis: A Population-Based Cohort Study","volume":"154","author":"Tsai","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e22014","DOI":"10.1016\/j.heliyon.2023.e22014","article-title":"Short-Term Efficacy and Safety of Biologics and Janus Kinase Inhibitors for Patients with Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1291\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:35:12Z","timestamp":1760027712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14041291"],"URL":"https:\/\/doi.org\/10.3390\/jcm14041291","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]}}}